Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific Inc. (NYSE: TMO) will announce its third-quarter 2021 financial results on October 27, 2021, before the market opens. A conference call will follow at 8:30 a.m. EDT, where the company will discuss its performance and future outlook. Interested parties can listen via phone or through the company’s website. With an annual revenue of approximately $35 billion, Thermo Fisher is committed to supporting scientific advancement and improving global health.
Thermo Fisher Scientific has priced an offering of €5.25 billion in euro-denominated senior notes through its wholly-owned subsidiary. The notes include €1.75 billion of 0.800% notes due 2030, €1.5 billion of 1.125% notes due 2033, €1.25 billion of 1.625% notes due 2041, and €750 million of 2.000% notes due 2051. Proceeds will fund the acquisition of PPD, Inc. The offering is expected to close around October 18, 2021, and is fully guaranteed by Thermo Fisher.
Thermo Fisher Scientific (NYSE:TMO) has taken operational control of a new biologics manufacturing site in Lengnau, Switzerland, as part of its partnership with CSL Limited. This facility spans 1.5 million square feet and will enhance production capabilities with bioreactors up to 12,500L. Approximately 200 employees will join Thermo Fisher. Initially, the site will support CSL's Idelvion® production for hemophilia B, with plans for further expansion to other biopharma clients. This move strengthens Thermo Fisher's global biologics manufacturing network, including locations in the US, Netherlands, Australia, and China.
Thermo Fisher Scientific (NYSE: TMO) announced its continued $7.5 million commitment for the 2021-2022 school year to support The Just Project, providing no-cost COVID-19 testing at over 60 historically black colleges and universities (HBCUs). The initiative aims to ensure campus safety amidst rising COVID-19 cases, having conducted over 50,000 tests last year with infection rates below 1%. Additionally, Thermo Fisher plans to hire more than 500 HBCU alumni over three years to promote diversity in its workforce.
Thermo Fisher Scientific Inc. (TMO) announced a $3 billion share repurchase authorization, effective immediately and with no expiration date. This new authorization replaces the previous one, which had $500 million remaining. The company's annual revenue stands at approximately $35 billion, emphasizing its position as a leader in serving science. The buyback aims to enhance shareholder value by reducing the number of shares outstanding, which can result in an increase in earnings per share (EPS).
Thermo Fisher Scientific (NYSE: TMO) will have its CEO, Marc N. Casper, present virtually at the JP Morgan 12th Annual U.S. All Stars Conference on September 22, 2021, at 9:00 a.m. EDT. This event showcases the company's commitment to advancing scientific research through innovative solutions. Thermo Fisher, with annual revenues of approximately $35 billion, serves a wide range of scientific needs globally.
Access the webcast via the Investors section of Thermo Fisher's website.
Thermo Fisher Scientific (NYSE: TMO) announced the launch of the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR system. This innovative technology aims to provide accurate and consistent results in just 90 minutes, enhancing applications in oncology and gene therapy. By acquiring Combinati's advanced dPCR technology, Thermo Fisher aims to expedite innovation in cancer research. The system simplifies workflows, reducing hands-on time to five minutes, minimizing user errors, and accelerating genetic analysis processes for biotech and academic institutions.
Thermo Fisher Scientific (NYSE: TMO) will host a virtual Investor Day on September 17, 2021, from 9:00 a.m. to 11:00 a.m. (EDT). The event will include presentations by senior management, followed by a Q&A session. Investors can access the live webcast through the company's website, with a replay available later. Thermo Fisher Scientific, a leader in serving science, reported annual revenues over $30 billion and employs over 80,000 colleagues to support life sciences research and laboratory productivity.
Thermo Fisher Scientific (NYSE: TMO) has secured a $192.5 million contract from the U.S. Department of Defense to boost domestic production of pipette tips, essential for research and diagnostics, including COVID-19 testing. The award includes co-investment in a new, energy-efficient manufacturing facility in North Carolina, set to commence operations by Q3 2023 and complete by Q3 2024. This initiative aims to enhance supply chain resilience and job creation while supporting the company’s net-zero carbon emissions goal by 2050.
Thermo Fisher Scientific has priced an offering of $3.1 billion in senior notes to finance the pending acquisition of PPD, Inc. The offering includes:
- $700 million of 1.750% senior notes due 2028
- $1.2 billion of 2.000% senior notes due 2031
- $1.2 billion of 2.800% senior notes due 2041